In Canada, the forecasted sales for respiratory system medicine show a steady increase from 2024 through 2028, starting at 56 and reaching 61.6 US Dollars PPP Per Capita. This marks a consistent growth with an annual increase of approximately 2.5%. The year-on-year percentage variation from 2025 to 2026 is 2.4%, maintaining a similar trend through to 2028. Employing the Compound Annual Growth Rate (CAGR) from 2024 to 2028 indicates an annual average growth of around 2.5%. The base year, 2023, saw sales of approximately 54.8 US Dollars PPP Per Capita.
Future trends to watch for include:
- Advancements in respiratory health treatments and pharmaceuticals
- Increasing prevalence of respiratory diseases due to environmental factors
- Impact of healthcare policies on pharmaceutical pricing and accessibility
- Technological innovations in medicine delivery methods and telehealth solutions
